2024
Breast Cancers Detected during a Decade of Screening with Digital Breast Tomosynthesis: Comparison with Digital Mammography.
Philpotts L, Grewal J, Horvath L, Giwerc M, Staib L, Etesami M. Breast Cancers Detected during a Decade of Screening with Digital Breast Tomosynthesis: Comparison with Digital Mammography. Radiology 2024, 312: e232841. PMID: 39287520, DOI: 10.1148/radiol.232841.Peer-Reviewed Original ResearchConceptsDigital breast tomosynthesisBreast cancerDigital mammographyAdvanced cancerHuman epidermal growth factor 2-positiveOverdiagnosis of breast cancerProportion of advanced cancersBreast cancer detection rateEffectiveness of digital breast tomosynthesisRate of advanced cancerDuctal carcinoma in situInterval cancer rateTwo-dimensional digital mammographyInvasive cancer sizeTriple-negative tumorsCancer detection rateCarcinoma in situBreast tomosynthesisFalse-negative findingsIncreased cancer detectionIncident screensIncident roundsAxillary nodesDM screeningInvasive cancer
2023
Surgical management of breast fat necrosis: Multi-institutional data analysis of early outcomes and risk factors for complications
Knoedler S, Knoedler L, Patel H, Diatta F, Camacho J, Sofo G, Perozzo F, Evans B, Mookerjee V, Ayyala H, Pomahac B, Kauke-Navarro M. Surgical management of breast fat necrosis: Multi-institutional data analysis of early outcomes and risk factors for complications. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 88: 292-295. PMID: 38029475, DOI: 10.1016/j.bjps.2023.11.015.Peer-Reviewed Original ResearchConceptsBreast fat necrosisChronic heart failureRisk factorsAdverse eventsHeart failureFemale patientsSurgical managementFat necrosisNational Surgical Quality Improvement ProgramSurgical Quality Improvement ProgramHigher wound classPostoperative adverse eventsNon-cancerous conditionsOutcomes of interestQuality Improvement ProgramMajority of casesPerioperative algorithmWound classComplication occurrenceComplication ratePostoperative outcomesSurgical complicationsMedical complicationsSurgical treatmentMultivariable analysisBreast implant capsule-associated squamous cell carcinoma: A systematic review and individual patient data meta-analysis
Yeow M, Ching A, Guillon C, Alperovich M. Breast implant capsule-associated squamous cell carcinoma: A systematic review and individual patient data meta-analysis. Journal Of Plastic Reconstructive & Aesthetic Surgery 2023, 86: 24-32. PMID: 37666057, DOI: 10.1016/j.bjps.2023.08.002.Peer-Reviewed Original ResearchConceptsIndividual patient dataSCC diagnosisPatient dataSystematic reviewJoanna Briggs Institute critical appraisal toolsDisease-free survivalMajority of patientsSquamous cell carcinomaRisk of biasRisk of malignancyCritical appraisal toolExtracapsular spreadMean followOverall survivalMedian ageMedian timeCell carcinomaBreast implantationImplant removalPatientsBreast augmentationUS FoodDrug AdministrationBreast implantsAppraisal toolEditorial Comment: Artificial Intelligence May Help Define Screening Strategies in Patients With Dense Breasts.
Butler R. Editorial Comment: Artificial Intelligence May Help Define Screening Strategies in Patients With Dense Breasts. American Journal Of Roentgenology 2023, 222: e2330042. PMID: 37556603, DOI: 10.2214/ajr.23.30042.Peer-Reviewed Original ResearchPACS-integrated machine learning breast density classifier: clinical validation
Lewin J, Schoenherr S, Seebass M, Lin M, Philpotts L, Etesami M, Butler R, Durand M, Heller S, Heacock L, Moy L, Tocino I, Westerhoff M. PACS-integrated machine learning breast density classifier: clinical validation. Clinical Imaging 2023, 101: 200-205. PMID: 37421715, DOI: 10.1016/j.clinimag.2023.06.023.Peer-Reviewed Original ResearchRisk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ
Kinslow C, Yu J, DeStephano D, Kachnic L, Cheng S, Neugut A, Horowitz D. Risk of Squamous Cell Carcinoma of the Breast Following Postmastectomy Implant Reconstruction in Women With Breast Cancer and Carcinoma in Situ. JAMA Surgery 2023, 158: 769-771. PMID: 37074722, PMCID: PMC10116379, DOI: 10.1001/jamasurg.2023.0262.Peer-Reviewed Original ResearchHow Does Reduction Mammaplasty Surgical Technique Impact Clinical, Aesthetic, and Patient-Reported Outcomes?
Cunning J, Mookerjee V, Alper D, Rios-Diaz A, Bauder A, Kimia R, Broach R, Barrette L, Fischer J, Butler P. How Does Reduction Mammaplasty Surgical Technique Impact Clinical, Aesthetic, and Patient-Reported Outcomes? Annals Of Plastic Surgery 2023, 91: 28-35. PMID: 37450858, DOI: 10.1097/sap.0000000000003610.Peer-Reviewed Original ResearchConceptsInferior pedicle techniqueQuality of lifePedicle techniqueInferior pedicle reduction mammoplastyBREAST-Q surveysGrade 3 ptosisPatient-reported outcomesShorter procedure timeInferior pedicle reductionReduction mammoplasty techniqueReduction mammaplasty techniquePostoperative complicationsPatient characteristicsSymptomatic macromastiaSingle surgeonWound dehiscenceMammoplasty techniqueSuperomedial pedicleReduction mammoplastyProcedure timePatientsComplicationsLife outcomesMammaplasty techniqueBreast aestheticsEstimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool
Leone J, Graham N, Leone J, Tolaney S, Leone B, Freedman R, Hassett M, Vallejo C, Winer E, Lin N, Tayob N. Estimating mortality in women with triple-negative breast cancer: The ‘ESTIMATE triple-negative’ tool. European Journal Of Cancer 2023, 189: 112930. PMID: 37356327, DOI: 10.1016/j.ejca.2023.05.018.Peer-Reviewed Original ResearchConceptsBreast cancer-specific mortalityTriple-negative breast cancerRisk of BCSMTumor characteristicsBreast cancerCumulative riskNon-metastatic triple-negative breast cancerMost tumor characteristicsCancer-specific mortalityRisk of deathPopulation-based riskHigh-grade triple-negative breast cancerCause mortalityMost patientsPathologic variablesInitial diagnosisHigh riskNew diagnosisPatientsMortalityDiagnosisYear 0RiskCancerWomenASO Author Reflections: Ancillary Treatment After Breast Cancer Surgery: Who are We Missing?
Chan V, Heller D, Sanft T. ASO Author Reflections: Ancillary Treatment After Breast Cancer Surgery: Who are We Missing? Annals Of Surgical Oncology 2023, 30: 5649-5650. PMID: 37179270, DOI: 10.1245/s10434-023-13507-2.Peer-Reviewed Original ResearchCoverage of Fertility Preservation and Treatment Among Surgical Trainees in the United States of America
Wo L, Eidelson S, Zheng C, Mouhanna J, Bussies P, Zhang C, Möller M. Coverage of Fertility Preservation and Treatment Among Surgical Trainees in the United States of America. Journal Of Surgical Education 2023, 80: 689-696. PMID: 36933957, DOI: 10.1016/j.jsurg.2023.02.012.Peer-Reviewed Original ResearchConceptsFertility preservationGeneral surgery residentsFertility servicesInsurance coverageFertility educationHigh-risk pregnanciesUS general surgery residency programsSurgical traineesGeneral surgery residency programsAssociated with female genderInfertility challengesInstitutional supportPearson chi-square testInstitutional coverageSurgery residency programsUnited States of AmericaFertile yearsFellowship program directorsUS general surgery residentsChi-square testStates of AmericaUnited StatesGS residentsSurgery traineesPerceived lackAdjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial
Tolaney S, Tarantino P, Graham N, Tayob N, Parè L, Villacampa G, Dang C, Yardley D, Moy B, Marcom P, Albain K, Rugo H, Ellis M, Shapira I, Wolff A, Carey L, Barroso-Sousa R, Villagrasa P, DeMeo M, DiLullo M, Zanudo J, Weiss J, Wagle N, Partridge A, Waks A, Hudis C, Krop I, Burstein H, Prat A, Winer E. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. The Lancet Oncology 2023, 24: 273-285. PMID: 36858723, DOI: 10.1016/s1470-2045(23)00051-7.Peer-Reviewed Original ResearchConceptsHER2-positive breast cancerInvasive disease-free survivalDisease-free survivalRecurrence-free intervalAdjuvant paclitaxelBreast cancerEastern Cooperative Oncology Group performance statusInvasive disease-free survival eventsDisease-free survival eventsHormone receptor-positive diseaseNew contralateral breast cancerBreast cancer-specific survivalProtocol-defined treatmentCancer-specific survivalReceptor-positive diseasePhase 2 studyContralateral breast cancerLong-term outcomesAPT trialCause deathEligible patientsIntravenous paclitaxelTrastuzumab weeklyDistant recurrenceIpsilateral recurrenceEvaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
Speers C, Symmans W, Barlow W, Trevarton A, The S, Du L, Rae J, Shak S, Baehner R, Sharma P, Pusztai L, Hortobagyi G, Hayes D, Albain K, Godwin A, Thompson A. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. Journal Of Clinical Oncology 2023, 41: 1841-1848. PMID: 36649570, PMCID: PMC10082279, DOI: 10.1200/jco.22.01499.Peer-Reviewed Original ResearchConceptsBreast Recurrence ScoreAnthracycline-based chemotherapyDisease-free survivalRecurrence scoreEndocrine therapyTherapy indexAdjuvant anthracycline-based chemotherapyNode-positive breast cancerAdjuvant endocrine therapyPrimary end pointSubset of patientsPostmenopausal patientsChemotherapy benefitTreatment armsPrognostic indexPrognostic informationBreast cancerPrognostic assessmentPrognostic performancePatientsEnd pointTumor samplesChemotherapyClinical validationProportional hazards assumption
2022
Survival in male breast cancer over the past 3 decades
Leone J, Freedman R, Leone J, Tolaney S, Vallejo C, Leone B, Winer E, Lin N, Hassett M. Survival in male breast cancer over the past 3 decades. Journal Of The National Cancer Institute 2022, 115: 421-428. PMID: 36583555, PMCID: PMC10086618, DOI: 10.1093/jnci/djac241.Peer-Reviewed Original ResearchConceptsBreast cancer-specific survivalMale breast cancerOverall survivalBreast cancerMultivariable Cox regressionCancer-specific survivalEnd Results registryYear of diagnosisBreast cancer mortalityStage of diseaseLog-rank testCox regressionCancer mortalityKaplan-MeierIndependent associationCox modelSignificant improvementSignificant associationCancerLife expectancyDiagnosisSurvivalSignificant differencesPatientsMenMultiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis
Garcia-Recio S, Hinoue T, Wheeler G, Kelly B, Garrido-Castro A, Pascual T, De Cubas A, Xia Y, Felsheim B, McClure M, Rajkovic A, Karaesmen E, Smith M, Fan C, Ericsson P, Sanders M, Creighton C, Bowen J, Leraas K, Burns R, Coppens S, Wheless A, Rezk S, Garrett A, Parker J, Foy K, Shen H, Park B, Krop I, Anders C, Gastier-Foster J, Rimawi M, Nanda R, Lin N, Isaacs C, Marcom P, Storniolo A, Couch F, Chandran U, Davis M, Silverstein J, Ropelewski A, Liu M, Hilsenbeck S, Norton L, Richardson A, Symmans W, Wolff A, Davidson N, Carey L, Lee A, Balko J, Hoadley K, Laird P, Mardis E, King T, Perou C. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer 2022, 4: 128-147. PMID: 36585450, PMCID: PMC9886551, DOI: 10.1038/s43018-022-00491-x.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerBreast cancerHER2-targeted therapiesImmune cell infiltratesMetastatic breast tumorsLiver metastasesCell infiltrateLow-pass whole-genome sequencingSubtype changesT cellsEstrogen receptorTumor subtypesEndothelial contentBreast tumorsMetastasisCell-cell adhesion genesReduced expressionGlobal DNA methylationDNA methylation mechanismsFocal deletionsMolecular featuresWhole-genome sequencingCancerSubtypesRNA sequencingImpact of early detection on cancer curability: A modified Delphi panel study
Schwartzberg L, Broder M, Ailawadhi S, Beltran H, Blakely L, Budd G, Carr L, Cecchini M, Cobb P, Kansal A, Kim A, Monk B, Wong D, Campos C, Yermilov I. Impact of early detection on cancer curability: A modified Delphi panel study. PLOS ONE 2022, 17: e0279227. PMID: 36542647, PMCID: PMC9770338, DOI: 10.1371/journal.pone.0279227.Peer-Reviewed Original ResearchConceptsBlood testsLikelihood of benefitCancer typesEarly detectionEarly cancer detectionSolid tumorsTotal cancer incidenceAmerican Joint CommitteeLow cure rateRAND/UCLAPotential clinical benefitCancer detectionDelphi panel studyLong cancerClinical benefitCure ratePotential benefitsCancer curabilityMost cancer typesCancer incidenceHigh curabilityJoint CommitteeTreat cancersExpert consensusPanel consensusOptoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study.
Seiler S, Neuschler E, Butler R, Lavin P, Dogan B. Optoacoustic Imaging With Decision Support for Differentiation of Benign and Malignant Breast Masses: A 15-Reader Retrospective Study. American Journal Of Roentgenology 2022, 220: 646-658. PMID: 36475811, DOI: 10.2214/ajr.22.28470.Peer-Reviewed Original ResearchEnsuring Both Accessibility and Usability of Breast Cancer Care
Oh S, Butler P. Ensuring Both Accessibility and Usability of Breast Cancer Care. Annals Of Surgical Oncology 2022, 30: 8-9. PMID: 36344712, DOI: 10.1245/s10434-022-12763-y.Peer-Reviewed Original ResearchRadiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None?
Moran M, Ho A. Radiation Therapy for Low-Risk Breast Cancer: Whole, Partial, or None? Journal Of Clinical Oncology 2022, 40: 4166-4172. PMID: 36332170, DOI: 10.1200/jco.22.01751.Peer-Reviewed Original ResearchConceptsWide local excisionPartial breast irradiationBreast cancerRadiation therapyEstrogen receptor-positive/progesteroneLow-risk breast cancerOncology Grand Rounds seriesHuman epidermal growth factor receptor 2Left-sided breast cancerWhole breast radiation therapyEpidermal growth factor receptor 2Clinical-pathologic featuresPostmenopausal female patientsDose/fractionationGrowth factor receptor 2Sentinel node biopsyOmission of radiationCommon clinical scenariosFactor receptor 2Node biopsyPostoperative radiationLocal excisionFemale patientsBreast irradiationTreatment recommendationsOutcomes of Extended Pedicle Technique vs Free Nipple Graft Reduction Mammoplasty for Patients With Gigantomastia
Talwar AA, Copeland-Halperin LR, Walsh LR, Christopher AN, Cunning J, Broach RB, Baratta MD, Copeland M, Shankaran V, Butler PD. Outcomes of Extended Pedicle Technique vs Free Nipple Graft Reduction Mammoplasty for Patients With Gigantomastia. Aesthetic Surgery Journal 2022, 43: np91-np99. PMID: 36161307, DOI: 10.1093/asj/sjac258.Peer-Reviewed Original ResearchConceptsFree nipple graftBREAST-Q scoresAesthetic outcomeReduction mammoplastyPropensity score-matched casesTertiary care centerPairs of patientsReduction mammoplasty techniqueMulti-institutional studyBaseline characteristicsAdult patientsClinical outcomesMedical complicationsPostoperative breastPostoperative cellulitisRetrospective studyMammoplasty techniqueNipple graftCare centerInclusion criteriaSurgical experiencePedicle techniquePostoperative photographsGigantomastiaHigh incidenceUnderstanding public perception of bra size
Malphrus E, Desai A, Weiss E, Couto J, Broach R, Butler P. Understanding public perception of bra size. Journal Of Plastic Reconstructive & Aesthetic Surgery 2022, 75: 4197-4201. PMID: 36180339, DOI: 10.1016/j.bjps.2022.08.038.Peer-Reviewed Original ResearchConceptsBreast cup sizeCup sizeGeneral population sampleSurvey respondentsBreast surgeryPostoperative resultsPreoperative discussionGeneral populationPatientsBra sizeBreastPersonal historyDemographic questionnairePopulation samplePreoperative imagesPatient's breastSurgeonsWomenUse QuestionnaireQuestionnaireFemale respondentsRespondentsSurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply